If that is the case:
"Sounds like they want the primary endpoints to include whether a person relapsed and the 'long term' effects. Basically the FDA seems to be saying - include additional descriptions for the endpoints and adjust the SAP to match. "
That, IMO is awesome news, and shows I was right. We need to target the Long haul Covid19 application, mutate/modify the trial into a drug for long haul covid19 and complete the take it right away on new infections EUA path.
That makes the up side on this % Billion dollar stock. I will be buying more shares now. And averaging down...
This could also sweeten the pot for a buy out for billions....
Bullish